Alerts will be sent to your verified email
Verify Email
CAPLIPOINT
|
Caplin Point Lab
|
Gufic Biosciences
|
Gland Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
20.61 % | 25.05 % | 12.02 % |
|
5yr Avg Net Profit Margin
|
24.8 % | 10.9 % | 20.79 % |
|
Price to Book
|
9.42 | 6.06 | 3.36 |
|
P/E
|
45.43 | 58.83 | 39.97 |
|
5yr Avg Cash Conversion Cycle
|
79.85 Days | 26.94 Days | 69.81 Days |
|
5yr Average Interest Coverage Ratio
|
579.71 | 13.1 | 183.05 |
|
5yr Avg ROCE
|
25.27 % | 27.25 % | 16.55 % |
|
5yr Avg Operating Profit Margin
|
30.87 % | 18.45 % | 29.26 % |
|
5 yr average Debt to Equity
|
0.01 | 0.51 | 0.01 |
|
5yr CAGR Net Profit
|
16.28 % | 14.26 % | -6.87 % |
|
5yr Average Return on Assets
|
17.7 % | 11.52 % | 10.65 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
70.56 % | 72.52 % | 51.83 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
1.68 % | -2.48 % | -6.04 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.87 % | 2.35 % | 15.13 % |
|
Caplin Point Lab
|
Gufic Biosciences
|
Gland Pharma
|
|---|